|
|
 | | | |
- close
- close
- close
- close
| |||||||||
This excerpt taken from the ACL 6-K filed Apr 24, 2008. LADAR6000™ systems from the market in the United States during 2007. Despite the decline in This excerpt taken from the ACL 20-F filed Mar 18, 2008. LADAR6000™
excimer laser. The Company removed all LADAR6000™
systems from the market in the United States during 2007. This decline was
offset by third-party sales of WaveLight products and procedure fees, totaling $15.1
million after we acquired a controlling interest in WaveLight in November 2007.
Consumer Eye Care
Our global consumer eye care sales, consisting of contact lens care and other general eye care products, grew 14.6% (11.5% in constant currency) to $786.0 million in the year ended December 31, 2007 compared to $685.6 million in 2006.
Sales of our contact lens disinfectants increased 18.8% in the year ended December 31, 2007 compared to the same period in 2006. Sales growth of our contact lens disinfectants reflected market share gains after a major competitor withdrew one of its leading products from the market during the second quarter of 2006. Another competitor recalled its product in May 2007. The withdrawals created an increase in demand for alternate products. Since our competitors' recalls, This excerpt taken from the ACL 6-K filed Jul 26, 2007. LADAR6000™ excimer laser. Until our investigation of these reports is complete, we expect that our future sales from per procedure technology fees will be reduced.
24
Consumer Eye Care
Our global consumer eye care sales, consisting of contact lens care and other general eye care products, grew 15.3% (13.2% in constant currency) to $392.8 million in the six months ended June 30, 2007.
Sales of our contact lens disinfectants increased 22.4% in the six months ended June 30, 2007 compared to the same period in 2006. Sales growth of our contact lens disinfectants reflected our success in gaining market share after a major competitor withdrew one of its leading products from the market during the second quarter of 2006. Another competitor recalled its product on May 25, 2007; however, the timing of the recall and the relative market share of the competitor's product recalled in the second quarter of 2007 was less than that related to the recall initiated in the same quarter of 2006.. The withdrawals created an increase in demand for alternate products. This excerpt taken from the ACL 6-K filed Apr 26, 2007. LADAR6000™ excimer laser. We have notified
the FDA of this situation and have submitted a Pre-Market Approval supplement with a proposed corrective action plan. Until the FDA responds to our Pre-Market Approval supplement,, we are unable to determine whether the associated costs will be significant. For the year ended December 31, 2006, our refractive sales were 1.1% of total sales, and we expect that our future sales from per procedure technology fees will be reduced.
Consumer Eye Care
Our global consumer eye care sales, consisting of contact lens care, artificial tears and other general eye care products, grew 19.6% (17.6% in constant currency) to $187.5 million in the three months ended March 31, 2007.
Sales of our contact lens disinfectants increased 31.3% in the three months ended March 31, 2007 compared to 2006. Sales growth of our contact lens disinfectants reflected our success in gaining market share after a major competitor withdrew one of its leading products from the market during the second quarter of 2006. The withdrawal created a surge in demand for alternate products. Since our competitor's recall, This excerpt taken from the ACL 6-K filed Mar 21, 2007. LADAR6000™ excimer laser. In some of these cases, patients exhibited a decrease in best corrected visual acuity. An
investigation is continuing to determine the cause of the reports. The U.S. Food and Drug Administration has been notified of this situation and management is working to determine an appropriate corrective action and has submitted a Pre-Market Approval supplement. Until corrective action is determined, the Group is unable to determine whether the associated costs will be significant. For the year ended December 31, 2006, the Group’s refractive sales were 1.1% of total consolidated sales, and it expects that its future sales from per procedure technology fees will be reduced.
60
This excerpt taken from the ACL 6-K filed Apr 25, 2006. LADAR6000TM excimer laser and expanded ranges of refractive correction.
Consumer Eye Care
Our global consumer eye care sales, consisting of contact lens care and other general eye care products, grew 4.4% (5.6% in constant currency) to $156.8 million in the three months ended March 31, 2006.
Sales of our contact lens disinfectants increased 2.5% in the three months ended March 31, 2006 compared to 2005, due to the launch of O | EXCERPTS ON THIS PAGE:
|
| |||||||
